Measuring visual field progression in the early manifest glaucoma trial

被引:212
|
作者
Heijl, A [1 ]
Leske, MC
Bengtsson, B
Bengtsson, B
Hussein, M
机构
[1] Malmo Univ Hosp, Dept Ophthalmol, SE-20502 Malmo, Sweden
[2] SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA
来源
ACTA OPHTHALMOLOGICA SCANDINAVICA | 2003年 / 81卷 / 03期
关键词
D O I
10.1034/j.1600-0420.2003.00070.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims: The Early Manifest Glaucoma Trial (EMGT) (316 eligible eyes) has used a new set of criteria to define visual field progression in glaucoma. This paper provides estimates of the amount of visual field worsening required to reach the EMGT definition of definite perimetric progression. Methods: In the 148 eyes that reached definite progression, we first determined changes between baseline and the time of definite EMGT progression, both for mean deviation (MD) and for number of highly (p < 0.5%) significantly depressed test points in pattern deviation probability maps. Second, we studied whether such changes depended on baseline MD, intraocular pressure (IOP), age and time to progression, all of which are factors that affect the rate of field progression. Results: In eyes reaching progression, the mean change in MD from baseline was -1.93 dB (SE +/- 0.20) and the mean change in number of significant points was +4.85 (SE +/- 0.35). These changes did not show linear dependency on baseline MD, IOP or time to progression. Conclusions: The average amount of field deterioration needed to reach EMGT visual field progression has been measured and expressed in more conventional units (i.e. a loss of about - 2dB in MD and an increase in about five highly significant points). These estimates will facilitate the clinical interpretation of the results of EMGT.
引用
收藏
页码:286 / 293
页数:8
相关论文
共 50 条
  • [31] Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial
    Heijl, Anders
    Peters, Dorothea
    Leske, M. Cristina
    Bengtsson, Boel
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 152 (05) : 842 - 848
  • [32] The early manifest glaucoma trial: Study aims and design.
    Heijl, A
    Leske, MC
    Bengtsson, B
    Hyman, L
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S567 - S567
  • [33] Early detection of visual field progression in glaucoma: a comparison of PROGRESSOR and STATPAC 2
    Viswanathan, AC
    Fitzke, FW
    Hitchings, RA
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1997, 81 (12) : 1037 - 1042
  • [34] Persistence of Glaucoma Therapy and Visual Field Progression
    de Leon, John Mark
    Quek, Desmond
    Htoon, Hla
    Lamoureux, Ecosse
    Aung, Tin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [35] Visual field progression outcomes in glaucoma subtypes
    De Moraes, Carlos Gustavo
    Liebmann, Jeffrey M.
    Liebmann, Craig A.
    Susanna, Remo, Jr.
    Tello, Celso
    Ritch, Robert
    ACTA OPHTHALMOLOGICA, 2013, 91 (03) : 288 - 293
  • [36] Visual Field Progression in Treated Glaucoma Patients
    Jonas, Jost B.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2012, 1 (03): : 127 - 128
  • [37] Estimating progression of visual field loss in glaucoma
    Katz, J
    Gilbert, D
    Quigley, HA
    Sommer, A
    OPHTHALMOLOGY, 1997, 104 (06) : 1017 - 1025
  • [38] Persistence of Glaucoma Therapy and Visual Field Progression
    de Leon, John M. S.
    Quek, Desmond T.
    Htoon, Hla M.
    Perera, Shamira A.
    Lamoureux, Ecosse L.
    Aung, Tin
    JOURNAL OF GLAUCOMA, 2016, 25 (04) : E336 - E339
  • [39] Visual field progression in patients with severe glaucoma
    Eugenio J. Maul
    Alan Kastner
    Jimena Schmidt
    Jaime A. Tapia
    Cristobal Morales
    Eugenio A. Maul
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 1579 - 1586
  • [40] Visual field progression in patients with severe glaucoma
    Maul, Eugenio J.
    Kastner, Alan
    Schmidt, Jimena
    Tapia, Jaime A.
    Morales, Cristobal
    Maul, Eugenio A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (06) : 1579 - 1586